Technology Commercialization and Intellectual Property/Patents

Patents, Patents Pending, Industry & Technology, Technological, and Other Scientific Innovations for Fiscal Year 2020.

Bradley J. Katz, MD, PhD

Bradley J. Katz, MD, PhD, founder and CEO of Axon Optics, axonoptics.com, joined with Tecport Optics to develop a ground-breaking optical interference filter coating process for plastic spectacle lenses. The process blocks the specific wavelengths of light that have been implicated as the cause of photophobic symptoms, particularly those associated with triggering and exacerbating debilitating migraine headaches. The University of Utah has registered the existing proprietary property.

Methods, systems, and apparatus for reducing the frequency and/or severity of photophobic responses or for modulating circadian cycles, Bradley J. Katz, Patent pending: China, Vol. 36, No. 2001, 2018800621910, Patent pending: Australia, 2018314216, 2018314216, Patent pending: India, 12/2020, 202017005351, Patent pending: European Patent Office (EPO), 3664745, 18843639.8, Patent pending: Republic of Korea, 10-2020-7003867, Patent pending: Canada, 3,072,541, Patent pending: South Africa, 2020/00810, Patent issued: United States, US-2017-0336545-A1, 15/673,26416/800,951, Patent pending: Singapore, 11202000912S, Patent pending: Japan, 2020-507060.

Methods, systems, and apparatus for modulating circadian cycles, Bradley J. Katz, Patent issued: United States, 16/445,085.

Nanoparticle light filtering method and apparatus, Bradley J. Katz, Patent pending: United States, US16/251,510, US20190154894A1, Patent pending: World Intellectual Property Organization (WIPO), WO2015073933A1, PCT/ US2014/065848.

Gregory S. Hageman, PhD

Gregory S. Hageman, PhD, is the John A. Moran Presidential Endowed Chair of Ophthalmology and Visual Sciences; executive director, Sharon Eccles Steele Center for Translational Medicine, specializing in the genetics and assessment of pathways involved in the etiology of age-related macular degeneration and retinal cell biology.

Methods of predicting the development of complementmediated disease, Gregory S. Hageman, Patent pending: United States, US-2020-0239958-A1, 16/734,168.

Methods of diagnosing and treating vascular associated maculopathy and systems thereof, Gregory S. Hageman, Patent pending: United States, 16/806,887.

Methods of predicting the development of AMD based upon chromosome 1 and chromosome 10, Gregory S. Hageman, Patent pending: United States, 16/806,906.

HTRA1 modulation for treatment of AMD, Gregory S. Hageman, Patent pending: World Intellectual Property Organization (WIPO), WO/2020/210724, PCT/ US2020/027802.

Gene therapy for macular degeneration and other chromosome 1-directed diseases, Gregory S. Hageman, Patent pending: World Intellectual Property Organization (WIPO), WO 2020/019002A1, PCT/US2019/042891.

Haibo Wang, MD, PhD, and Mary Elizabeth Hartnett, MD

Haibo Wang, MD, PhD, and Mary Elizabeth Hartnett, MD, specialize in the mechanisms of normal and aberrant angiogenesis, particularly related to diabetic retinopathy, retinopathy of prematurity, and AMD.

Methods and compositions for the expression of constitutively active RAP1A from a VMD2 promoter, Haibo Wang and Mary Elizabeth Hartnett, Patent pending: United States, 62/905,880.